El.En. SpAELEAF 74 5-Year ROIIC % is 43.85 as of Dec. 2025. GuruFocus rates ELEAF with a GF Score™ of 74/100 and a GF Value™ of $15.66 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 734 Medical Devices & Instruments companies, El.En. SpA ranks better than 84.47% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
El.En. SpA's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was 43.85%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for El.En. SpA's 5-Year ROIIC % or its related term are showing as below:
ELEAF's 5-Year ROIIC % is ranked better than 84.47% of 734
companies
in the Medical Devices & Instruments industry
Industry Median: 1.025
vs ELEAF: 43.85
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
El.En. SpA 5-Year ROIIC % Related Terms
El.En. SpA 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for El.En. SpA's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, El.En. SpA's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
El.En. SpA 5-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, El.En. SpA's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where El.En. SpA's 5-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
El.En. SpA (ELEAF) has a 5-Year ROIIC % of 43.85 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on El.En. SpA and its competitors. According to the industry distribution chart, El.En. SpA ranks #114 out of 734 companies in the Medical Devices & Instruments industry, placing it in the top 15.5%.
Is El.En. SpA's 5-Year ROIIC % too high?
El.En. SpA's current 5-Year ROIIC % is 43.85. The Medical Devices & Instruments industry median 5-Year ROIIC % is 1.03. El.En. SpA's value of 43.85 is 4178% above this industry median. Based on the distribution chart, El.En. SpA ranks #114 out of 734 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, El.En. SpA has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does El.En. SpA's 5-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, El.En. SpA ranks #114 out of 734 companies for 5-Year ROIIC %. This places El.En. SpA in the top 16% of its industry — outperforming the majority of peers. The industry median 5-Year ROIIC % is 1.03. El.En. SpA's value of 43.85 is 4178% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Medical Devices & Instruments company?
The median 5-Year ROIIC % among Medical Devices & Instruments companies is 1.03, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. El.En. SpA's current 5-Year ROIIC % of 43.85 is 4178% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on El.En. SpA and its competitors. For the Medical Devices & Instruments industry, the median 5-Year ROIIC % is 1.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. El.En. SpA's current 5-Year ROIIC % is 43.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El.En. SpA stock overvalued right now?
Based on GuruFocus' analysis, El.En. SpA (ELEAF) is currently considered Modestly Overvalued. The stock's GF Value™ is $15.66, compared to a current price of $18.50 — trading 18.1% above its estimated fair value. The current 5-Year ROIIC % is 43.85 and 4178% above the Medical Devices & Instruments industry median of 1.03. El.En. SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For El.En. SpA (ELEAF), the current 5-Year ROIIC % is 43.85 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is El.En. SpA (ELEAF) Overvalued in 2026?
Based on GuruFocus' analysis, El.En. SpA stock appears to be overvalued.
The current stock price of $18.50 is trading 18.1% above its estimated GF Value™ of $15.66.
GuruFocus considers El.En. SpA to be Modestly Overvalued.
Key valuation signals for ELEAF:
5-Year ROIIC %: 43.85
GF Value™: $15.66 vs. price of $18.50 (18.1% above fair value)
Industry Position: 4178% above the Medical Devices & Instruments median (#114 of 734)
No single metric tells the full story. See the ELEAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
El.En. SpA is engaged in the research and development, manufacturing, distribution, and sales of laser systems. The company operates in two divisions: medical and industrial. In the medical division, the application of laser is used as a healing treatment for aesthetic, surgical, physiotherapy and dental. Industrial division develops solutions for laser material processing applications through cutting, marking, laser sources and restoration. The company generates the majority of its revenue from the medical division. Geographically, it derives maximum revenue from the Rest of the World.
74GF Score
Get the complete analysis for ELEAF
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELEAF has been successfully added to your 
